U.S., April 11 -- ClinicalTrials.gov registry received information related to the study (NCT06922604) titled 'Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma' on April 03.
Brief Summary: This phase Ib trial tests the safety and side effects of glofitamab after pre-treatment with obinutuzumab and how well they work in treating patients with central nervous system (CNS) lymphoma. Glofitamab is a bispecific antibody that can bind to two different antigens (substances that cause the body to make a specific immune response) at the same time. Glofitamab binds to CD20 on lymphoma cells, and CD3 on T-cells (a type of white blood cell) and may interfere with the ability of cancer cells to grow and spr...